COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit . What Should Hims & Hers Investors Do?

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Ali Eastburn missed her son’s rehearsal dinner — and nearly missed the wedding — when her appendix burst while traveling, ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...